What is Constructive Bio?
Constructive Bio operates at the vanguard of synthetic biology, specializing in the creation of entirely synthetic genomes and the reprogramming of genetic codes within living organisms. The company's core platform technology is designed to engineer virus-resistant organisms and convert cellular structures into sustainable bio-factories. This approach enables the production of advanced materials and therapeutic agents that were previously unattainable through traditional chemical synthesis. By effectively turning biology into a programmable medium, Constructive Bio is establishing a new paradigm for sustainable manufacturing, positioning itself as a critical infrastructure provider for the future of biotechnology and material science.
How much funding has Constructive Bio raised?
Constructive Bio has raised a total of $73M across 2 funding rounds:
Angel/Seed
$15M
Series A
$58M
Angel/Seed (2022): $15M, investors not publicly disclosed
Series A (2024): $58M led by Omx Ventures, Ahren Innovation Capital, Paladin Capital Group, NanoDimension, and Fine Structure Ventures
Key Investors in Constructive Bio
Omx Ventures
OMX Ventures is a biotechnology investment firm that focuses on transforming groundbreaking discoveries into scalable biotech companies, leveraging data and artificial intelligence.
Ahren Innovation Capital
Ahren Innovation Capital is an investment institution focused on supporting transformational companies at the intersection of deep technology and deep science.
Paladin Capital Group
Paladin Capital Group operates as a global multi-stage investment firm specializing in venture capital and growth financing across diverse sectors.
What's next for Constructive Bio?
With the recent capital deployment, Constructive Bio is expected to scale its operational capacity and expand its intellectual property portfolio. The company's strategic roadmap likely involves transitioning from laboratory-scale proof-of-concept to industrial-grade production environments. As the firm continues to refine its genetic reprogramming tools, the focus will shift toward securing high-value partnerships in the pharmaceutical and material science sectors. The current funding environment suggests that Constructive Bio will prioritize the commercialization of its bio-factory platform, aiming to demonstrate the economic viability of synthetic biology in large-scale manufacturing applications. Future milestones will likely center on regulatory validation and the expansion of its proprietary technology stack to address complex industrial challenges.
See full Constructive Bio company page
